Quantum X Labs posted revenue of $293,000 for the quarter ended June 30, 2026, down 20.81% year over year.
Revenue for H1 FY26 fell 28.82% to $646,000.
The operating loss widened to $1.95 million in Q2 FY26.
Research and development expense climbed to $185,000 from $20,000, reflecting consolidation of Quantum Israel after the March 2026 acquisition.
General and administrative expense rose to $1.02 million from $558,000, on higher professional services costs and consolidation-related expenses.
Net financial expense narrowed to $113,000 from $7.66 million, as prior-year results included fair-value financing expenses tied to facility agreements.
Results included a $3.83 million gain from deconsolidating CliniQuantum following a June 2026 third-party purchase of about 54.01% of its equity.
QXL•
